In complex therapeutic algorithms for cancer, regional intra-arterial chemotherapy is usually used as an adjuvant and placed in the beginning of treatment. Clinical experience however shows that the achieved remission of malignant tumour illness after non-adjuvant chemotherapy is only temporary and short-lived. The illness progresses relatively quickly if the patient receives no further treatment and most clinical studies have not found any signifi cant increase in life expectancy in oncological patients treated with this method. The question remains to what extent the poor results are due to the treatment method and its position in the therapeutic algorithm, and to what extent they are due to imperfect knowledge of molecular tumour genetics or inappropriate choice of the neoadjuvant intra-arterial chemotherapy Methods: We compared preliminary results of immunohistochemical examinations (detection and analysis of expression of proteins Ku 70, STAT 1,3,5 which take part in the regulation of cell cycle apoptosis and repair of damaged DNA, carried out before and after chemotherapy, suggest that depending on the eff ects of neoadjuvant intra-arterial chemotherapy and patient's survivance.
INTRODUCTION
The incidence of oropharyngeal carcinoma in various parts of the world ranges from 1-10 cases per 100,000 inhabitants though its occurrence is extremely high in Southeast Asia.
No doubt it is infl uenced by genetic factors, lifestyle and level of prevention. In the Czech Republic, the occurrence of oropharyngeal carcinoma (2.6/100,000 inhabitants) corresponds to the European average for men, while it is above average in females. Surgical removal of the tumour continues to be a fi rst choice of basic therapeutic options (surgery, radiotherapy, chemotherapy). Radiotherapy is usually placed in the end of the therapeutic cycle (adjuvant radiotherapy) or as the main therapeutic method in inoperable tumours or in tumour recurrences.
Chemotherapy has a rather adjuvant signifi cance in the algorithm of treatment for oropharyngeal carcinoma. Systemic administration of cytostatics in combination with radiotherapy can increase tumour radiosensitivity and improve the fi nal eff ect of treatment. There is no uniform view on the inclusion of chemotherapy at the beginning of combined treatment (neoadjuvant chemotherapy) with the aim of reducing tumour volume and establishing conditions for its successful surgical removal. In the area of head and neck, the tumour is relatively well supplied with blood (mostly via a.carotis ext. and its ventral branches) and it is possible to administer the cytostatic directly to the aff erent artery (regional intraarterial chemotherapy). The advantages of this treatment modality involve achieving optimum concentration of cytostatic in tumour tissue, reducing the total therapeutic dose, limiting systemic side eff ects and cutting down the total costs of treatment.
Critics of the use of neoadjuvant inta-arterial chemotherapy in orofacial oncology point to the fact that this treatment procedure does not infl uence signifi cantly the overall success of cancer treatment or survival time of patients 2, 17, 18, 20 . Clinical experience has shown that the therapeutic eff ect of neoadjuvant chemotherapy is only temporary, relatively short-lived and cannot be estimated in advance. If a patient does not receive additional treatment for some reason, the illness progresses relatively quickly. The reasons for the time-limited eff ect of neoadjuvant chemotherapy are not completely clear. One possible explanation involves diff erences in chemotherapy-induced expression of several proteins taking part in the regulation of the tumour growth. One known negative consequence of neoadjuvant intra-arterial chemotherapy involves remission of macroscopically apparent tumour edges, which is associated with risk of insuffi cient radicality during subsequent surgical removal.
Indication of Intra-arterial Chemotherapy of Oropharyngal Carcinoms
Regional intra-arterial chemotherapy is indicated in patients in stags III and IV of malignant tumour illness treatment. It should be included the beginning of complex at treatment as the fi rst treatment modality (tumour vascularity should not be altered by previous surgical events or radiotherapy). Considering the time-limited therapeutic effects, it is not appropriate to use regional chemotherapy as a palliative treatment procedure in incurable tumours.
When assessing indications for intra-arterial chemotherapy of oropharyngeal carcinoma, the following is taken into account:
• Stage of the malign tumour illness, • Prior therapeutic events, • Tumour localisation, • Overall health and age of the patient, • Mental state of the patient, assumptions for collaboration with physician.
The patient's good health and interest in collaboration with physician are important prerequisites for successful utilisation of the method. Therefore, we do not recommend regional chemotherapy in patients with serious liver or kidney illnesses, alcoholics, uncooperative, disoriented or immobile patients.
The method is relatively safe and has a low percentage of complications, but it is still necessary to bear in mind that the insertion of an intra-arterial cannula in close vicinity to carotid (for instance in chemotherapy of laryngeal carcinoma) can be associated with increased risk of embolism in the central nervous system via a.carotis int.
Intra-arterial Chemotherapy Technique
Intra-arterial chemotherapy is principally based on administration of cytostatic to the area which is supplied by an appropriate artery. In the orofacial area, this mostly involves one of the ventral branches of a. carotis externa (according to the localisation of the tumour). A cannula is inserted • directly into an appropriate artery (direct method), • to a. carotis externa via a. thyroidea sup. (indirect method), • to a. carotis externa via a. temporalis superfi c. (retrograde method).
An alternative method consists in the use of a portcatheter, implanted into subcutis in the area of the mastoid process or under the clavicle, and leading into chosen artery.
Of the above, it seems most advantageous to use retrograde cannulation via a. temporalis superfi cialis. The blood vessel is accessed via a 4-5 cm long vertical skin incision, approximately 1 cm forward of tragus (ear). Following arteriotomy, we insert the cannula approximately 10 cm, check the correct localisation of the cannula and the range of perfused area perisurgically using a colorimetric test (Patentblau). It is also possible to check the position of the cannula arteriographically, but it is much more demanding from a technical and fi nancial point of view. Then, we secure the cannula with stitches and connect it to an infusion pump. The infusion solution (physiological solution, 5% glucose solution) contains a cytostatic as well as low-molecular heparin and an analgetic with a spasmolytic eff ect (e.g. Prokain). Movement of patient during a treatment cycle, which lasts for 6-8 days, is spatially limited. In any event, the range of extension of the infusion allows him/her to move around the room with access to washbowl and toilet. The advantage and pitfalls of regional intra-arterial chemotherapy are given in Table 1 .
The complications marked in italics are marked enough to discontinue treatment prematurely.
Table 1. Advantages and pitfalls of regional intra-arterial chemotherapy

Advantages of intra-arterial chemotherapy Disadvantages of intra-arterial chemotherapy
Achieving optimum concentration of the cytostatic in tumour tissue
Short-term therapeutic eff ect
Reduction of the total dose of a cytostatic = lower system toxicity
Risk of intra-arterial thrombosis with subsequent vascular brain accident
Lowering the risk of system side eff ects, fi nancial savings
Regional skin and mucous reaction (dermatitis, stomatitis, alopecia)
Unpleasant subjective feelings (burning etc.) in the perfused area
Technical complications (dislocation or obturation of intra-arterial cannula) Intra-arterial chemotherapy and its signifi cance in the treatment of oropharyngeal carcinoma
Cytostatics suitable for use in regional intra-arterial chemotherapy are divided according to their chemical composition and mechanism of interference with the cellular cycle (Tab. 2) 
Metotrexate (MTX)
The MTX mechanism is based on competitive inhibition of dihydropholate reductase, which transforms folic acid (or, more accurately, dihydrofolic acid) into tetrahydrofolic acid, an important cofactor in the biosynthesis of purines. The fi nal eff ect involves a blockade of DNA synthesis and cell division. Dihydrofolate reductase inhibition can be prevented by simultaneous delivery of reduced folates (folinic acid, leucovorin), which are used in practice as chemoprotectives. MTX selectively inhibits cell division in the S-phase of the cell cycle, and actively proliferating tissues are more sensitive to the eff ects of the antimetabolite. The cytostatic penetrates the cell via an active transport mechanism but in cases of impaired function it causes resistance to MTX in tumour cells 1, 6, 27 . This can be overcome by increasing the dose of cytostatic and concurrent administration of leucovorin as a chemoprotective.
Pyrimidine analogues (uracil analogues, fl uroinated pyrimidines)
5-fl uoruracil (5-FU) is a pyrimidine antimetabolite with a multiple manner of interference with DNA biosynthesis. In the cell cycle, it especially acts in the S-phase, and partly slows down the transition G1-S. Antitumour effects can be reinforced by concurrent administration of reduced folates (leucovorin). 5-fl uorouracil metabolises quickly in the body (in liver) to dihydro-5-fl uorouracil; approximately 20 % is excreted in urine in an unchanged form (the half-time is 10-15 minutes). The swift decline in plasma concentration after single administration explains why continual infusion manifests more marked antitumour effi ciency 8, 10, 12, 13 .
Platinum derivatives
Cisplatin (DDP) has a similar mechanism to alkylating compounds. These bind with the nitrogen in purine and pyrimidine in the DNA molecule. DDP potentiates the cytotoxic eff ect of many other cytostatics (vincristin, vinblastin, 5-fl ourouracil) 30, 32 and has specifi city for any phase of the cell cycle. It has marked immunosuppressive eff ects. After systemic administration, DDP is transported to tissues very swiftly and concentrates especially in kidney, liver and gonads. It is excreted into urine in three phases. The half time of the rapid phase is 8-50 minutes, 16 hours for the medium phase and 5 days for the slow phase. In hydrous solution, especially with alkaline pH, hydrolysis occurs at a rate which can restrict higher concentrations of chloride ions. This is why a physiological or Ringer's solution is used for infusion treatment and not the 5% glucose. A serious undesirable eff ect of DDP is nephrotoxicity which can be eliminated by correct hydration regime.
Carboplatin is a second-generation cisplatin derivative. It is a cytostatic eff ective in the treatment of a wide spectrum of malignant neoplasms. The biochemical properties and the mechanisms of eff ect are similar to those of DDP. The antitumour activity of platinum derivatives is mostly based in DNA synthesis inhibition; however, participation of other mechanisms, e.g. immunosuppressive or radiosensibilising ones, cannot be excluded.
Substances with a radiomimetic eff ect
Bleomycin (BLM) is a polypeptide antibiotic isolated from Streptomyces verticillus. It has weak antimicrobial and marked cancerostatic eff ects. The exact mechanism of its eff ect is unknown but the results of its action resemble the eff ects of radioactive radiation. It mainly functions in the G2-phase of the cell cycle. BLM is mostly metabolised in kidney and liver.
Mitosis inhibitors
Vinca alkaloids are preparations that damage the structure and function of the microtubules of the dividing spindle which provides for correct migration of chromosomes prior to cell division. Most of these cytostatics restrict the synthesis of tubulin, the protein of which the spindle is built. The vinca alkaloids block the mitosis process by inhibiting the production, or destruction, of microtubules. Vinblastin has a synergistic eff ect with Bleomicin. Vincristin (VCR) has similar chemical and physical properties, is phase-specifi c, infl uences permeability of membranes and hence potentiates the eff ect of other cytostatics.
Taxans (taxoids) represent a relatively new group of substances with an antitumour eff ect. They involve substances of natural origin isolated from yew (Taxus breviofolia, Taxus baccata). Taxans cause mitosis inhibition by blockade of tubulin depolymerisation. Taxans also block the transition from the G2-M-phase and have a radiopotentiating eff ect, as the cells, which occur at this phase, are more vulnerable to ionising radiation. They then block the cell response to growth factors, inhibit production of the "tumour necrosis factor" and are mediators of apoptosis. They have been produced synthetically since 1994 (e.g. Paclitaxel, Docetaxel, Taxol)
The mechanism of antitumor activity of paclitaxel is not known exactly 30, 32 . It has been reported to support the aggregation of microtubules from tubulin dimers to prevent their depolymerisation. The subsequent stabilisation then results in the inhibition of normal dynamic reorganisation of the microtubular assembly, necessary for interphase and mitotic cell functions. It then induces abnormal arrangement of microtubules leading to the development of multiple microtubular asters during mitosis. After administration, 88-98 % bind to plasma proteins, and the plasma concentration decreases in a biphasic manner. The large distribution indicates extensive extravascular or binding to tissue. Renal excretion is not signifi cant in the case of paclitaxel: less than 10 % of the dose administered is excreted unchanged in urine. Metabolism with subsequent excretion into bile is the main elimination route.
Choice and algorithm of cytostatic administration in regional intra-arterial chemotherapy
Chemotherapy of oropharyngeal carcinoma began to be used clinically in the 1960s. The results of monotherapy were not very encouraging. A combination of Metotrexat and Bleomycin in various regimes was then used. 15-50 % remission was achieved in this manner. The introduction of cisplatin and its analogues was another step forward. Table 3 .
The table shows that combinations DDP+FU, DDP+BLM, DDP+BLEO+MTX were the most successful 4, 31 . In the 1990s, promising results using taxans (Paclitaxel) in combination with carboplatin were reported. Nevertheless, an analysis of the results showed that no randomised, well-designed study has demonstrated the contribution of chemotherapy to survival extension in oncological patients.
Signifi cance of immunohistochemical examination for an estimation of the eff ect of chemotherapy
One possibility for evaluating in advance the reaction of cells to treatment is to determine the level of TPS marker or acid phosphatase. TPS is a non-specifi c marker which responds to the increased proliferating activity of cells in the S2-phase of mitosis. Comparing the TPS level at the beginning and during treatment shows a reduction in TPS level when the response is positive (approximately 70 % success). At the same time, the activity of the acid phosphatase also increases with increasing damage to tumour. It would be much more useful to know the response of tumour prior to treatment and thus modify the therapy be optimal. The approach could to consist in the detection and analysis of the expression of selected regulators of the cell cycle of malignant tumours (Ka70, STAT 1,3,5), which are signifi cant for tumour invasivity and development of antitumor immunity. Similarly, genetic screening (comparing genetic damage and response to cytostatic treatment) can assist in determining the chemosensitivity of tumour cells. This method seems very promising and if it is successful, one could speak of targeted cytostatic treatment (comparable to the relationship between bacteria cultivation and microbiological examination with targeted antibiotic treatment).
CONCLUSION
Intra-arterial neoadjuvant chemotherapy of head and neck tumours has held an irreplaceable position in the treatment of oncological illnesses of the orofacial area. Especially in the beginning of the 1960s, it was considered a huge step forward and it could have seemed that the issue of tumour treatment was "resolved" to a certain degree. As with any other new treatment method however, the advantages and complications emerged over time. Moreover, it has become apparent that tumour volume reduction (which is only partial in an overwhelming majority of cases) is only temporary. In more than 90 % of cases, the eff ect is short-term and the tumour progresses again in several weeks 3, 25 . For this reason chemotherapy began to be used as an adjuvant at the beginning of complex antitumor treatment.
The initial optimism, associated with the introduction of regional intra-arterial chemotherapy when tumours responded very well to treatment with cytostatics (e.g. Bleomycin), was replaced by scepticism 5, 26, 29 . We currently often encounter zero therapeutic response or even a progression of the tumoral illness during chemotherapy. This explains why there have been eff orts to determine tumour chemosensitivity prior to treatment.
An opinion which cast doubts on the therapeutic signifi cance of regional intra-arterial chemotherapy has prevailed over the last two decades 28 . This follows from the fact that no clinical study has found any extension of life-span in oncological patients treated using this method. Nonetheless, we can still ask today to what extent the poor results not below are due to the treatment method and its inclusion in the therapeutic algorithm, and to what extent they are conditioned by imperfect knowledge of molecular tumour genetics or inappropriate choice of cytostatic.
